Key Highlights
- Third-quarter 2026 Revenue was $30.6 million, against $27.8 million a year earlier, up 10%.
- Commercial Channel revenue was $14.0 million, up approximately 17%, and OEM Channel revenue was $16.6 million, up approximately 5%.
- Adjusted EBITDA was $5.1 million, and adjusted Net Income from continuing operations was $3.9 million, or $0.29 per diluted share.
- Gross Margin was 62%, against 56% in the prior-year period.
- Cash and cash equivalents were $45.0 million as of Sept. 30, 2026.
Anika Therapeutics (NASDAQ:ANIK), the Bedford, Massachusetts-based developer and manufacturer of hyaluronic acid products, reported third-quarter 2026 results on Friday before the market opened. Total revenue was $30.6 million, compared with $27.8 million a year earlier. Market estimates had pointed to revenue of $29.44 million and Earnings of $0.42 per share.
Adjusted net income from continuing operations was $3.9 million, or $0.29 per diluted share, and Adjusted EBITDA was $5.1 million. International viscosupplement revenue increased 19% and total Regenerative Solutions revenue increased 12%. Integrity revenue grew more than 30% year over year.
Channel Results and Strategy Updates
Commercial Channel revenue was $14.0 million and OEM Channel revenue was $16.6 million. Through the first nine months, Commercial Channel revenue increased 15% and OEM Channel revenue increased 11%.
The company secured a new 10-year Hyvisc Partnership with enhanced Economics and reintroduced its Hyaff non-orthopedic OEM product. Gross margin improved year over year on Manufacturing productivity, partly offset by product mix from the reintroduction of Hyalomatrix, a Hyaff wound product.
Pipeline Developments
Enrollment in the Cingal bioequivalence study was completed in September. Anika expects to submit the Cingal new drug application before year-end 2027. In October, the FDA notified the company that the Hyalofast premarket approval application is not approvable, primarily based on the clinical data in the submission. Anika said it continues to assess available options.
Guidance for 2026 and 2027
For 2026, Anika now guides to total company revenue growth of 6% to 10%, from 5% to 10%. OEM Channel growth is guided at 5% to 9%, from 0% to 5%, and Commercial Channel growth at 9% to 13%, from 12% to 18%. Adjusted EBITDA margin is guided at 15% to 17%, from 13% to 17%.
For 2027, the company reaffirmed total revenue growth of flat to 5%, with OEM Channel revenue flat to modestly lower and Commercial Channel growth of 5% to 15%.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...